AbCellera Biologics Inc. (ABCL) Stock Analysis

Q: What is the ABCL stock price target?

Take-profit $8.27 (+101.5% upside). Prior stop was $3.82.

Q: Is ABCL overvalued or undervalued?

AbCellera Biologics Inc. trades at a P/E of N/A (forward -4.9). TrendMatrix value score: 5.4/10. Overall verdict: Sell.

Q: What do analysts say about ABCL?

14 analysts cover ABCL with a consensus score of 4.1/5. Average price target: $10.

Recovery setup

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Sell if holding. Engine safety override at $4.12: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 18.67; Below-average business quality.

$4.12+101.5% A.UpsideScore 4.9/10#93 of 158 Biotechnology

Stop $3.82Target $8.27(analyst − 13%)A.R:R 6.8:1

Analyst target$9.50+130.6%6 analysts

$8.27our TP

$4.12price

$9.50mean

$12

Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (2.1 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-4.9

Mkt Cap$1.2B

EV/EBITDA-3.9

Profit Mgn-194.9%

ROE-14.5%

Rev Growth788.2%

Beta0.85

DividendNone

Rating analysts14

Quality Signals

Piotroski F4/9

Options Flow

P/C18.67bearish

IV107%elevated

Max Pain$2-51.5% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.415%0.81

Quality2.115%0.32

Growth5.015%0.75

Momentum5.510%0.55

Sentiment7.710%0.77

Insider Activity6.510%0.65

Peer Rank4.110%0.41

Technical Setup3.15%0.16

Risk Profile2.75%0.14

Catalyst6.45%0.32

Overall (Σ contributions)4.87

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roe

0.0

Roa

0.0

Operating Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Current Ratio

5.0

Moat

5.0

Cash-burning: FCF -234% of revenueNo competitive moatQuality concerns

Volatile — 6.1% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Put Call

0.0

Implied Vol

0.0

Short Interest

1.5

Max Pain Risk

3.0

Beta

7.9

Debt Equity

9.4

High short interest justified: 20%Elevated put/call: 18.67High IV: 107%Above max pain $2

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger

2.4

Support Resistance

2.4

52w Position

2.6

Gap

5.0

GatesEARNINGS PROXIMITY 11d<=14d (soft)Momentum 5.5>=5.5A.R:R 6.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive

RSI

68 · Neutral

↑ 20D MA↑ 50D MA↓ 200D MADEATH CROSSSupport $3.22Resistance $4.38

Price Targets

A.Upside+100.7%

A.R:R6.8:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (2.1 < 4.0)

Earnings

2/4 beats

Next Earnings2026-05-11 (11d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is ABCL stock a buy right now?

Sell if holding. Engine safety override at $4.12: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 18.67; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 68. Prior stop was $3.82. Score 4.9/10, moderate confidence.

What is the ABCL stock price target?

Take-profit target: $8.27 (+101.5% upside). Prior stop was $3.82. Stop-loss: $3.82.

What are the risks of investing in ABCL?

Quality below floor (2.1 < 4.0).

Is ABCL overvalued or undervalued?

AbCellera Biologics Inc. trades at a P/E of N/A (forward -4.9). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about ABCL?

14 analysts cover ABCL with a consensus score of 4.1/5. Average price target: $10.

What does AbCellera Biologics Inc. do?AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet...

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.